EX-10.2
EX-10.2
CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.
CONSULTING AGREEMENT
This Consulting Agreement (“Agreement”) is entered into as of April 20, 2026, (the “Effective Date”), between AnaptysBio, Inc., a Delaware corporation having its principal place of business in San Diego, California (“Company” or “Anaptys”), and Daniel Faga, an individual whose address is [*] (“Consultant”, and collectively with the Company, the “Parties”).
WHEREAS, the Company will complete a distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”), a wholly owned subsidiary of the Company (the “Transaction”), which is anticipated to be completed on April 20, 2026;
WHEREAS, TRAX is a newly formed public company; and
WHEREAS, Consultant has agreed to provide consulting services to the Company following the Transaction, on the terms and conditions set forth in this Agreement;
…